ProfessorPK Bondy (ChesterBeattyResearch Institute):
Combined treatment using hormones, radiotherapy and cytotoxics probably produces the best results. Hormonal treatment should be designed to take maximum advantage of all three modalities. Medical treatment, so far, should be considered palliative and should take second place to curative methods of treatment, when these are appropriate. Dr Graham Bennette (British Cancer Council): 'Responsiveness' of a tumour is a manifestation of a behaviour pattern, not a tumour 'property'. Potential responsiveness means that a tumour may alter its characteristics according to the environment. Full investigations of hormonal assays might be helpful in *detecting trends in the patterns of responsiveness.
Mr T Hamilton (Edinburgh): I hope that treatment of -the disease will be rationalized. No one treatment is so effective as to be considered preferential. Visible deposits may regress whereas occult metastases may continue to develop. The validity of the term 'response to hormonal treatment' has to be questioned. Professor Sir David Smithers (Royal Marsden Hospi-.tal): More attention should be paid to the possibilities of using endocrine methods in the prevention of the disease. There is a reduced incidence of mammary cancer in women who become pregnant before the age of 30 and in those who have an oophorectomy before the age of 35.
Dr I W F Hanham
(Westminster Hospital, London SWI)
Chemotherapy in Breast Cancer
Chemotherapy has in the past been the poor relation in the treatment of breast cancer. In the advanced cases, manipulation of the hormone status has been extensively explored, whereas ,chemotherapy tends, with some clinicians, to be a last resort and in some centres to be avoided altogether because of unpleasant side-effects.
In certain clinical situations, when disease is disseminated or locally recurrent after radiotherapy, chemotherapy rather than hormone treatment is more likely to be effective. These situations arise with inflammatory or rapidly growing carcinoma, with a short clinical history of disease, in the immediate postmenopausal patient or where there is a short time-interval between primary and secondary disease. Chemotherapy is also indicated where patients have failed to respond to, or relapse after, hormone therapy.
Anticancer drugs are given as adjuvants to radiotherapy or surgery; or as single agents by continuous, cyclical or 'pulse' treatments. Today they are also extensively used in combined drug regimes, such as 'quadruple chemotherapy'.
Oncologists are now familiar with the value of single-agent chemotherapy in breast cancer, with 5-fluorouracil or cyclophosphamide producing remission in 30-50 % of advanced cases; unfortunately these remissions are often short-lived but can occasionally be dramatic and prolonged.
Following the success of new quadruple combination regimes in lymphomas and leukxemias, our centre (Hanham et al. 1971 ) initiated a pilot study using a combination of four drugs; this was a modification of the regime used by Costanzi & Coltman (1969) , but substituting vinblastine for vincristine to reduce neurotoxicity.
The 1973 quadruple schedule, which is given every three or four weeks, is as follows: Days 1 and 5, cyclophosphamide 200-300 mg i.v.; Days 1 and 4, methotrexate 10-15 mg i.v.; Days 2 and 5, vinblastine 4-6 mg i.v.; Days 1 to 5, 5-fluorouracil 500 mg i.v. daily.
To date, 70 cases of advanced breast cancer have been treated and 37 (53%) are still alive: 7 patients have survived 24 months, 17 over 12 months and 13 over 6 months. Many of this group would have been considered untreatable by conventional means; particularly interesting was the response achieved in those patients with jaundice due to liver involvement (Fig 1) , cancer en cuirasse of the chest wall (Fig 2) , and intractable bone pain, which had not improved with radiotherapy or hormones. Remissions were also obtained in cases where there was failure of hormone control and rapid deterioration, and in cases where relapse occurred after long-term remission with hormone treatment.
Of the 70 patients, all of whom had had previously accepted modes of treatment either by hormones or single-agent chemotherapy, and had recurrent disease, only 6 failed to respond to quadruple chemotherapy, 50 % were in remission for up to 12 months, 30% up to 24 months and 
